HRT and Blood Clot Risk During Perimenopause: Everything You Need to Know
Understand VTE risk with oral vs transdermal HRT in perimenopause. Covers who is at higher risk, NICE guidance, and comparison with the combined pill.
What Are Blood Clots and Why Does HRT Get Linked to Them?
Venous thromboembolism (VTE) refers to blood clots forming in a vein, most commonly a deep vein thrombosis (DVT) in the leg or a pulmonary embolism (PE) when a clot reaches the lungs. VTE can be life-threatening, so any treatment linked to an increased risk warrants careful consideration. HRT came under scrutiny for VTE risk partly because the combined oral contraceptive pill, which contains synthetic oestrogen, significantly raises clot risk. Early HRT formulations contained oral oestrogen, and studies found these did carry a meaningful increase in VTE risk. However, the relationship between HRT and blood clots depends entirely on the route of administration. Oral oestrogen is processed through the liver on its first pass, which alters clotting factors in ways that raise VTE risk. Transdermal oestrogen, delivered through the skin via patches, gels, or sprays, bypasses this first-pass liver metabolism entirely and does not appear to increase VTE risk in healthy women at average baseline risk. This distinction is critical and has fundamentally changed how modern HRT is prescribed.
Oral vs Transdermal HRT: The Evidence on VTE
The ESTHER study and subsequent observational research have consistently shown that transdermal oestrogen does not significantly increase the risk of VTE compared with no HRT, while oral oestrogen is associated with an approximately doubling of VTE risk relative to non-use. It is important to contextualise that doubling: the baseline risk of VTE in healthy women in their late 40s and 50s is low, so even a doubling still represents a small absolute number. But for women who already have elevated baseline risk, oral oestrogen becomes a more significant concern. The NICE menopause guideline (updated 2023) explicitly states that transdermal HRT is not associated with an increased risk of VTE compared with oral preparations and recommends transdermal routes for women at higher VTE risk. The progestogen component also plays a role. Micronised progesterone and the Mirena coil appear to carry the lowest thrombotic risk among progestogens. Norethisterone and medroxyprogesterone acetate used orally may add some additional risk when combined with oral oestrogen. For most women, choosing a transdermal oestrogen with a low-risk progestogen effectively eliminates the meaningful VTE concern.
Who Is at Higher Risk of VTE?
Certain women have a meaningfully elevated baseline risk of blood clots and need extra care when considering HRT. Risk factors include a personal history of DVT or PE, a known inherited thrombophilia such as factor V Leiden or prothrombin gene mutation, active cancer or recent cancer treatment, severe obesity (BMI over 40), prolonged immobility, recent major surgery, and severe varicose veins with phlebitis. Smoking also raises VTE risk. A strong family history of clotting disorders, particularly in first-degree relatives who had a VTE before the age of 45, is also a flag for further investigation before starting HRT. Women with a personal history of VTE are not automatically excluded from HRT but should be assessed by a haematologist or menopause specialist before starting. In many cases, transdermal oestrogen can be used safely even in women with a prior clot, as long as it is combined with anticoagulation if appropriate and managed carefully. Thrombophilia testing is recommended for women with a strong family history before prescribing.
How HRT Compares to the Combined Pill
Many women taking the combined oral contraceptive pill before perimenopause are surprised to learn that the pill carries a higher VTE risk than modern HRT, including oral forms. The combined pill uses ethinylestradiol, a potent synthetic oestrogen that has a much stronger effect on liver clotting factors than the oestradiol used in HRT. The VTE risk with the combined pill is estimated at roughly 3 to 9 times the baseline risk depending on the progestogen used, compared with approximately 2 to 3 times with oral HRT oestrogen. Transdermal HRT, again, does not meaningfully raise VTE risk at all. This context is helpful for women who have been using the pill comfortably for years and worry that HRT is more dangerous. In practice, the pill is also often continued into perimenopause to manage irregular periods and provide contraception, even though HRT would address symptoms more effectively. Switching from the pill to transdermal HRT, with a separate progestogen-only contraceptive for pregnancy prevention, can be a better approach for women approaching their mid-40s whose VTE risk from the pill now outweighs the benefits.
NICE Recommendations for Prescribing and Monitoring
NICE guidelines are clear that transdermal oestrogen should be the preferred route for women with any risk factors for VTE. For average-risk women, both oral and transdermal preparations are options, but transdermal is increasingly the standard first choice in UK clinical practice given its more favourable cardiovascular and thrombotic profile. Women who are already on therapeutic anticoagulation for another reason can generally use HRT, including oral forms, though this should be managed by a specialist. NICE also recommends that women be given information about the signs and symptoms of DVT and PE when starting HRT, regardless of formulation, so they can act promptly if they notice unexplained leg swelling, pain, or difficulty breathing. Routine blood tests to screen for thrombophilia are not recommended for all women, only for those with a significant personal or family history. Annual HRT reviews should include reassessment of any new risk factors, such as changes in weight, smoking status, or mobility that might alter the risk-benefit balance.
Making an Informed Choice About Your HRT Route
Understanding the VTE evidence should be reassuring for most women in perimenopause considering HRT. The risk with transdermal oestrogen is genuinely not a significant concern for healthy women at average clot risk. The key message is that the route of administration matters far more than whether a woman uses HRT at all. A woman switching from oral HRT to a patch or gel does not lose any symptom-relief benefit but does gain a substantially better safety profile for blood clot risk. For women who prefer tablets and have no VTE risk factors, oral HRT remains a reasonable choice, with the understanding that the absolute excess risk is still small. Any woman who is unsure about her personal VTE risk should discuss this with a GP or menopause specialist before starting HRT. A menopause clinic will be able to take a full clotting history, identify any risk factors, test for thrombophilia where appropriate, and recommend the safest and most effective formulation for her individual situation.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.